EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis

Colin W Howden, Philip Katz iD, Kenneth R DeVault, David C Metz, David Tamene, Neila Smith, Barbara Hunt, Yu-Ming Chang, Stuart J Spechler

Alimentary Pharmacology & Therapeutics · 2025-03 · 61 (5) · 835-851

DOI: 10.1111/apt.18458 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-12-25. Written by Colin W Howden and 8 co-authors. Institution: University of Tennessee College of Medicine, Memphis, Tennessee, USA. Major MEDLINE topics: Sulfonamides, Pyrroles, Proton Pump Inhibitors, Gastroesophageal Reflux. Cited 18 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Phathom Pharmaceuticals Inc..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Patients with erosive oesophagitis, and those with persistent symptomatic non‐erosive gastro‐oesophageal reflux disease, require long‐term maintenance treatment with acid‐suppressing agents.

Aim

To evaluate the safety of vonoprazan, a potassium‐competitive acid blocker, in an integrated analysis of data from clinical trials in adults.

Methods

We included 14 clinical trials of vonoprazan conducted in multiple countries. Mean duration of exposure in person‐years to vonoprazan ( n = 5318) was 2068, to comparators lansoprazole ( n = 1925) or esomeprazole ( n = 86) was 751, and to placebo ( n = 779) was 59. We report adverse events, serum gastrin, and liver enzyme levels as the main outcomes. Post‐marketing safety data from December 26, 2014 (date of commercialisation in Japan) to December 25, 2023, are also provided.

Results

Nasopharyngitis was the only adverse event reported by at least 5.0% of patients (6.94% vonoprazan, 5.07% proton pump inhibitor (PPI), 4.49% placebo). Incidence rates per 100 person‐years for serious adverse events were 10.39 for vonoprazan, 10.65 for PPIs, and 1.69 for placebo. One patient each on vonoprazan and lansoprazole was diagnosed with gastric cancer. Mean serum gastrin levels were higher on vonoprazan than lansoprazole but normalised by 4 weeks after discontinuation. Elevated liver enzyme levels were infrequent and of low magnitude with no differences between vonoprazan and PPIs. There were four deaths; none was considered related to study drug.

Conclusions

Vonoprazan was well tolerated. Its safety profile from both clinical trial and post‐marketing data were consistent and comparable to that of its PPI comparators with respect to treatment‐emergent adverse events.

Subjects

MeSH terms (MEDLINE)

SulfonamidesPyrrolesProton Pump InhibitorsGastroesophageal RefluxEsophagitis, PepticEsophagitisHumansMaleFemaleMiddle AgedAdultLansoprazoleAgedEsomeprazoleTreatment OutcomeNasopharyngitis

Author keywords

erosive oesophagitisgastro‐oesophageal reflux diseasepotassium‐competitive acid blockervonoprazan

Substances

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineSulfonamidesPyrrolesProton Pump InhibitorsLansoprazoleEsomeprazole

Authors and institutions

  • University of Tennessee College of Medicine, Memphis, Tennessee, USA.
  • Division of Gastroenterology & Hepatology, Weill Cornell Medicine, New York, New York, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
  • Phathom Pharmaceuticals, Florham Park, New Jersey, USA.

ORCID profiles: Philip Katz

Funding

  • Phathom Pharmaceuticals Inc.

Cite

APA

Howden, C. W., Katz, P., DeVault, K. R., Metz, D. C., Tamene, D., Smith, N., Hunt, B., Chang, Y. M., & Spechler, S. J. (2025). Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics, 61(5), 835-851. https://doi.org/10.1111/apt.18458

Vancouver

Howden CW, Katz P, DeVault KR, Metz DC, Tamene D, Smith N, et al. Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics. 2025;61(5):835-851. doi:10.1111/apt.18458

BibTeX
@article{Howden2025,
  author = {Howden, Colin W and Katz, Philip and DeVault, Kenneth R and Metz, David C and Tamene, David and Smith, Neila and Hunt, Barbara and Chang, Yu-Ming and Spechler, Stuart J},
  title = {Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {5},
  pages = {835--851},
  doi = {10.1111/apt.18458}
}
Start for free →